Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05983523 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 54 | PharmaEngineINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06190886 | A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 26 | Proviva Therapeutics, Inc.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06622486 |
| First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors |
| recruiting |
| Phase 1 / Phase 2 |
| 50 |
| Egle TherapeuticsINDUSTRY |
| 2 |
| Nov 7, 2024 |
| clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05772455 | A Study of XZB-0004 in Patients With Solid Tumors | recruiting | Phase 1 | 128 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT04492488 | A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer | active not recruiting | Phase 1 / Phase 2 | 129 | Shanghai Miracogen Inc.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT04093466 | A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors | recruiting | Phase 1 | 126 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04387916 | A Study of KC1036 in Patients with Advanced Solid Tumors | recruiting | Phase 1 | 207 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06632574 | A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02521844 | A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | active not recruiting | Phase 1 | 89 | EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesOTHER_GOV | 2 | Oct 8, 2024 | clinicaltrials |
| NCT06621615 | Clinical Study of CVL006 Injection in Advanced Solid Tumors | not yet recruiting | Phase 1 | 120 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05765032 | Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 220 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06615193 | A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor | recruiting | Phase 1 | 111 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT03891706 | Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 30 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05367778 | Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 176 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05773937 | A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors | recruiting | Phase 1 | 40 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06525298 | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | recruiting | Phase 1 / Phase 2 | 144 | Eisbach Bio GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589401 | Oral Paclitaxel for Patients with Advanced Solid Tumors | recruiting | Phase 1 | 70 | InnoUp Farma S.L.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592417 | To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 140 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594874 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | not yet recruiting | Phase 1 | 350 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06548672 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | recruiting | Phase 1 | 148 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06452160 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 103 | BridGene Biosciences Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06364501 | Phase 1 Trial of KH801 | not yet recruiting | Phase 1 | 17 | Beijing Kanghong Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06536400 | Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 316 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT05474859 | Subjects With Advanced or Metastatic Solid Tumor Malignancies | not yet recruiting | Phase 1 | 30 | Xenthera, Inc.INDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06257680 | A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Beijing Xunsheng Biomedical Research Co., Ltd.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06528249 | Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies | not yet recruiting | Phase 1 | 39 | Zhejiang Provincial People's HospitalOTHER | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06514651 | MAQ-001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | MabQuest SAINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05878691 | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | active not recruiting | Phase 1 | 320 | Glenmark Specialty S.A.INDUSTRY | 2 | Jul 22, 2024 | clinicaltrials |
| NCT06332170 | ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 610 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06336707 | HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 1,048 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05979155 | A Study of NWY001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 196 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06477614 | Anti-cancer DC Cell Vaccination to Treat Solid Tumors | recruiting | Phase 1 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195293 | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195384 | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05532696 | Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | recruiting | Phase 1 / Phase 2 | 61 | Anbogen Therapeutics, Inc.INDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04592653 | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)(ARTISTRY-3) | active not recruiting | Phase 1 / Phase 2 | 78 | Mural Oncology, IncINDUSTRY | 2 | Jun 7, 2024 | clinicaltrials |
| NCT06081907 | The Efficacy and Safety of IBI363 in Solid Tumors(Promise) | recruiting | Phase 1 / Phase 2 | 430 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2024source: clinicaltrials